Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Other analysts also recently issued reports about the company. Wedbush lifted their target price on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Oppenheimer reiterated an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tyra Biosciences has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $26.29 on Friday. The firm has a market capitalization of $1.40 billion, a P/E ratio of -14.06 and a beta of 1.07. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $27.66. The company’s 50-day moving average is $20.69 and its 200 day moving average is $14.94.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). Research analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert J. More sold 246,871 shares of Tyra Biosciences stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the transaction, the director directly owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. This trade represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TYRA. Jacobs Levy Equity Management Inc. boosted its stake in Tyra Biosciences by 23.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company’s stock valued at $2,807,000 after acquiring an additional 57,556 shares in the last quarter. Polar Asset Management Partners Inc. boosted its position in shares of Tyra Biosciences by 27.1% in the 1st quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company’s stock worth $1,314,000 after purchasing an additional 30,134 shares in the last quarter. Corton Capital Inc. purchased a new position in Tyra Biosciences during the 2nd quarter worth $233,000. Dynamic Technology Lab Private Ltd acquired a new position in Tyra Biosciences during the 2nd quarter valued at about $326,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Tyra Biosciences in the second quarter valued at about $177,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.